Abstract
Background The SARS-CoV-2 transmission dynamics have been greatly modulated by human contact behaviour. To curb the spread of the virus, global efforts focused on implementing both Non-Pharmaceutical Interventions (NPIs) and pharmaceutical interventions such as vaccination. This study was conducted to explore the influence of COVID-19 vaccination status and risk perceptions related to SARS-CoV-2 on the number of social contacts of individuals in 16 European countries. This is important since insights derived from the study could be utilized in guiding the formulation of risk communication strategies.
Methods We used data from longitudinal surveys conducted in the 16 European countries to measure social contact behaviour in the course of the pandemic. The data consisted of representative panels of participants in terms of gender, age and region of residence in each country. The surveys were conducted in several rounds between December 2020 and September 2021. We employed a multilevel generalized linear mixed effects model to explore the influence of risk perceptions and COVID-19 vaccination status on the number of social contacts of individuals.
Results The results indicated that perceived severity played a significant role in social contact behaviour during the pandemic after controlling for other variables. More specifically, participants who perceived COVID-19 to be a serious illness made fewer contacts compared to those who had low or neutral perceptions of the COVID-19 severity. Additionally, vaccinated individuals reported significantly higher number of contacts than the non-vaccinated. Further-more, individual-level factors played a more substantial role in influencing contact behaviour than country-level factors.
Conclusion Our multi-country study yields significant insights on the importance of risk perceptions and vaccination in behavioral changes during a pandemic emergency. The apparent increase in social contact behaviour following vaccination would require urgent intervention in the event of emergence of an immune escaping variant. Hence, insights derived from this study could be taken into account when designing, implementing and communicating COVID-19 interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work received funding from the European Research Council (ERC) under the European Unions Horizon 2020 research and innovation program (Grant Agreement 682540 TransMID). This project has received funding from the European Unions Horizon 2020 research and innovation programme - project EpiPose (Grant agreement number 101003688). This work reflects only the authors view. The European Commission is not responsible for any use that may be made of the information it contains. The work also received funding from the European Centre for Disease Prevention and Control (ECDC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in different countries and thus the approvals were sought from every country. They are listed as follows: In Austria, Ethikkommission der Stadt Wien Waived ethical approval for this work; In Denmark,The Central Denmark Region Committees on Health Research Ethics Waived approval for this work; In France, DCRI Centre Hospitalier Universitaire de Poitiers Waived approval for this work; In Poland, Komisja Bioetyczna Narodowego Instytutu Zdrowia Publicznego Panstwowego Zaldadu Higieny, Warszawa gave approval for this work; In Portugal, Comissã o de Ètica para a Saú de do Instituto Nacional de Saú de Doutor Ricardo Jorge gave Approval of the work; In Spain, Comitè Ètica de la Investigaciòn del Hospital Universitari Germans Trias i Pujol gave approval of the work; In Italy, Comitato di Bioetica d'Ateneo, Università degli studi di Torino gave approval of the work; In Finland, Institutional Review Board of the Finnish Institute for Health and Welfare waived the approval of the work; In Switzerland, Gesundheits-, Sozial- und Integrationsdirektion Kantonale Ethikkommission für die Forschung gave approval of the work; In Lithuania, LITHUANIAN BIOETHICS COMMITTEE waived the approval of the work; In Greece, Research Ethics Committee (E.H.D.E.)University of West Attica (PADA) gave approval of the work; In Slovenia, Komisija Republike Slovenije za medicinskoetiko (KME RS) gave approval of the work; In Croatia, Etiko povjerenstvo Hrvatskog zavoda za javno zdravstvo (HZJZ) gave approval of the work; In Estonia, Research Ethics Committee of the National Institute for Health Development gave approval of the work; In Hungary, Research Ethics Committee of the National Institute for Health Development gave approval of this work; In Slovakia, Eticka komisia Univerzita Komenskeho v Bratislave Jesseniova lekarska fakulta v Martine gave approval for this work;
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets utilized in this study are available in the Zenodo-based repository, www.socialcontactdata.org/data
https://www.bsg.ox.ac.uk/research/publications/variation-government-responses-covid-19
List of abbreviations
- ECDC
- European Centre for Disease Prevention and Control
- HERA
- Health Emergency Preparedness and Response Authority
- NPI
- Non-Pharmaceutical Intervention
- HBM
- Health Belief Model
- PMS
- Protection Motivation and Self-efficacy
- UK
- United Kingdom
- OxCGRT
- Oxford COVID-19 Government Response Tracker
- GLMM
- Generalized Linear Mixed effects Model
- SD
- Standard Deviation
- CI
- Confidence Interval
- GEE
- Generalized Estimating Equations NA : Not Applicable
